Asked by: Lord Black of Brentwood (Conservative - Life peer)
Question to the Department for Business, Energy and Industrial Strategy:
To ask Her Majesty’s Government what plans they have to conduct a review into competition between, and pricing of, district heating networks.
Answered by Baroness Neville-Rolfe - Shadow Minister (Treasury)
At present, there are no plans for the government to conduct a formal review into competition between, and pricing of, the heat network industry. The Government monitors these issues as part of its implementation of the Heat Network Investment Project and the development of the market more generally.
Asked by: Lord Black of Brentwood (Conservative - Life peer)
Question to the Department for Business, Energy and Industrial Strategy:
To ask Her Majesty’s Government how many customers have switched their energy provider in the last five years.
Answered by Baroness Neville-Rolfe - Shadow Minister (Treasury)
Data is published by the Department for Business, Energy and Industrial Strategy on switching. The data is collected by Ofgem and republished by BEIS in Table 2.7.1 of which can be found online (https://www.gov.uk/government/statistical-data-sets/quarterly-domestic-energy-switching-statistics ). Multiple switches made by the same customer in each year are counted as separate switches.
Year | Number of electricity switches | Number of gas switches |
2011 | 4,206,000 | 3,270,000 |
2012 | 3,342,000 | 2,280,000 |
2013 | 3,425,000 | 2,190,000 |
2014 | 3,058,000 | 2,281,000 |
2015 | 3,396,000 | 2,709,000 |
Asked by: Lord Black of Brentwood (Conservative - Life peer)
Question to the Department for Business, Energy and Industrial Strategy:
To ask Her Majesty’s Government what discussions they have had with the pharmaceutical company Gilead Sciences about the extension of its patent for the drug tenofovir.
Answered by Baroness Neville-Rolfe - Shadow Minister (Treasury)
We are not aware of any such discussions. We are aware of three supplementary protection certificates (SPCs) granted in the UK to Gilead Sciences for products involving tenofovir disoproxil fumarate, of which one has been surrendered and two are the subject of revocation proceedings.